Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.04 +0.84 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
40 41 Next >
News headline image
Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal ↗
NVAX stock is rising higher after the biotechnology company announced that it had signed a licensing deal with Sanofi. 
Via InvestorPlace
News headline image
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement ↗
Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi. 
Via Investor's Business Daily
News headline image
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern ↗
Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update. 
Via Benzinga
News headline image
Why Is Novavax (NVAX) Stock Up 118% Today? ↗
Novavax stock is up on Friday after the vaccine company announced a licensing agreement with Sanofi as its Q1 earnings report. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning! 
Via InvestorPlace
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
3 Biotech Stocks to Sell in May Before They Crash & Burn ↗
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
News headline image
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac ↗
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing. 
Via Benzinga
Topics Lawsuit
News headline image
Sanofi's New Cancer Drug Could Help Deliver a Big Payday ↗
Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib. 
Via The Motley Fool
News headline image
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation ↗
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond ↗
It pays to develop novel medicines for life-threatening illnesses. 
Via The Motley Fool
News headline image
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
From Pinnacle Group International
Via ACN Newswire
News headline image
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
News headline image
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study ↗
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
Via Benzinga
News headline image
Sanofi (SNY) Q1 2024 Earnings Call Transcript ↗
SNY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings ↗
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to... 
Via Benzinga
News headline image
SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024 ↗
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags ↗
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
News headline image
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
News headline image
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
News headline image
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed. 
Via Benzinga
News headline image
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
News headline image
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity ↗
Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates. 
Via Benzinga
News headline image
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
News headline image
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says ↗
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
News headline image
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
News headline image
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says ↗
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
News headline image
Why Is Auddia (AUUD) Stock Up 192% Today? ↗
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent. 
Via InvestorPlace
Topics Artificial Intelligence
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.